FBXO22在卵巢癌中的表达和临床意义

Expression and clinical significance of FBXO22 in ovarian cancer

目的研究FBXO22（F—boxonlyprotein22）蛋白在卵巢癌中的表达及与卵巢癌临床病理因素的关系。方法应用免疫组化SP法检测251例卵巢癌组织、10例癌旁组织中FBXO22的表达情况。251例年龄19—76岁，中位年龄49岁。病理分级：1级62例，2级79例，3级110例。临床分期：Ⅰ期175例，Ⅱ期35例，Ⅲ期31例，Ⅳ期10例。比较FBXO22在卵巢癌组织和癌旁组织中的阳性率，分析FBXO22的表达与卵巢癌临床病理因素的关系。结果FBXO22在卵巢癌中表达阳性率[31．1％（78／173）]明显高于癌旁组织[0（0／10）]，差异有统计学意义（P=0．035）。FBX022阳性率在不同临床分期（P〈0．001）和病理分级（P=0．015）中差异均有统计学意义，且临床分期及病理分级越高，FBXO22阳性率越高。结论FBXO22在卵巢癌组织中的表达明显高于癌旁正常组织，并与患者的临床病理因素相关。FBXO22有望成为卵巢癌诊断的重要标志物。

Objective To investigate the expression of FBXO22 （ F - box only protein 22） in ovarian cancer and its relationship with the clinical pathological factors of ovarian cancer. Methods The expression of FBXO22 in 251 ovarian cancer samples and 10 tumor- adjacent tissues were detected by immunohistochemistry. The 251 patients aged 19 -76 years, with the median age of 49 years. Pathological classification： 62 patients in Grade I, 79 in Grade II and 110 in Grade III. Clinical stage： 175 patients at Stage I, 35 at Stage II, 31 at Stage III and 10 at Stage IV. The positive rate of FBXO22 in ovarian cancer and tumor - adjacent tissues was compared, while the relationship between the expression of FBXO22 and the elinicopathologieal factors of ovarian cancer was analyzed. Results The positive rate of FBXO22 in o- varian cancer was 31.1% （78/173）, which was significantly higher than that in tumor - adjacent tissues [0 （0/10） ] （ P = 0.035 ）. The level of FBXO22 was associated with the pathological grade and clinical stage of ovarian cancer （ P 〈 0.05 ）. Conclusions The expression of FBXO22 in ovarian cancer tissues is significantly higher than that in normal adjacent tissues, and related to the clinieopathologieal factors of the patients. FBXO22 is expected to be an important marker for the diagnosis of ovarian cancer.